RASTOGI, PRACHI
RASTOGI, PRACHI
Lasing from dot-in-rod nanocrystals in planar polymer microcavities
2018-01-01 Manfredi, G.; Lova, P.; Di Stasio, F.; Rastogi, Prachi; Krahne, R.; Comoretto, D.
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
2026-01-01 Garber, J E; Cameron, D; Campbell, C; Yothers, G; Taboada, M; El-Abed, S; Rastogi, P; Mcconnell, R; Correa, A; Delaloge, S; Liu, W T; Sharma, P; Bergh, J; Janni, W; Balmaña, J; Loman, N; Španić, T; Friedman, S; Freeman, T; Armstrong, A; Korde, L; Im, S; Sagara, Y; Viale, G; Bliss, J; Vernazza, Gianni; Jóhannsson, Ó; Zoppoli, G; De Dueñas, E Martinez; Marmé, F; Fein, L; Arnedos, M; Ford, J; Schmutzler, R; Loibl, S; Linderholm, B; Lakhani, S R; Gnant, M; Gelmon, K; Domchek, S M; Senkus, E; Eisen, A; Jager, A; Piccart, M; Phillips, K A; Traina, T; Stickeler, E; Singer, C F; Shao, Z; Liu, X; Tipping, H; Aktan, G; Martinez, M; Canon, J L; Takahashi, M; Yasojima, H; Middleton, K; Pristauz-Telsnigg, G; Pfeiler, G; Virani, S; Valdes-Albini, F; Wolmark, N; Mesa, I Diaz; Paterson, V; Gelber, R D; Geyer, C E; Tutt, A N J
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
2019-01-01 Von Minckwitz, G.; Huang, C. -S.; Mano, M. S.; Loibl, S.; Mamounas, E. P.; Untch, M.; Wolmark, N.; Rastogi, Prachi; Schneeweiss, A.; Redondo, A.; Fischer, H. H.; Jacot, W.; Conlin, A. K.; Arce-Salinas, C.; Wapnir, I. L.; Jackisch, C.; Digiovanna, M. P.; Fasching, P. A.; Crown, J. P.; Wulfing, P.; Shao, Z.; Caremoli, E. R.; Wu, H.; Lam, L. H.; Tesarowski, D.; Smitt, M.; Douthwaite, H.; Singel, S. M.; Geyer, C. E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Lasing from dot-in-rod nanocrystals in planar polymer microcavities | 1-gen-2018 | Manfredi, G.; Lova, P.; Di Stasio, F.; Rastogi, Prachi; Krahne, R.; Comoretto, D. | |
| Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial | 1-gen-2026 | Garber, J E; Cameron, D; Campbell, C; Yothers, G; Taboada, M; El-Abed, S; Rastogi, P; Mcconnell, R; Correa, A; Delaloge, S; Liu, W T; Sharma, P; Bergh, J; Janni, W; Balmaña, J; Loman, N; Španić, T; Friedman, S; Freeman, T; Armstrong, A; Korde, L; Im, S; Sagara, Y; Viale, G; Bliss, J; Vernazza, Gianni; Jóhannsson, Ó; Zoppoli, G; De Dueñas, E Martinez; Marmé, F; Fein, L; Arnedos, M; Ford, J; Schmutzler, R; Loibl, S; Linderholm, B; Lakhani, S R; Gnant, M; Gelmon, K; Domchek, S M; Senkus, E; Eisen, A; Jager, A; Piccart, M; Phillips, K A; Traina, T; Stickeler, E; Singer, C F; Shao, Z; Liu, X; Tipping, H; Aktan, G; Martinez, M; Canon, J L; Takahashi, M; Yasojima, H; Middleton, K; Pristauz-Telsnigg, G; Pfeiler, G; Virani, S; Valdes-Albini, F; Wolmark, N; Mesa, I Diaz; Paterson, V; Gelber, R D; Geyer, C E; Tutt, A N J | |
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer | 1-gen-2019 | Von Minckwitz, G.; Huang, C. -S.; Mano, M. S.; Loibl, S.; Mamounas, E. P.; Untch, M.; Wolmark, N.; Rastogi, Prachi; Schneeweiss, A.; Redondo, A.; Fischer, H. H.; Jacot, W.; Conlin, A. K.; Arce-Salinas, C.; Wapnir, I. L.; Jackisch, C.; Digiovanna, M. P.; Fasching, P. A.; Crown, J. P.; Wulfing, P.; Shao, Z.; Caremoli, E. R.; Wu, H.; Lam, L. H.; Tesarowski, D.; Smitt, M.; Douthwaite, H.; Singel, S. M.; Geyer, C. E. |